Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT07311746RecruitingPhase 1/Phase 2
Study of cladribine, ruxolitinib, and venetoclax for T-PLL
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
Houston, TexasAges 18 years+ - NCT07551427RecruitingPhase 2
Testing TQ05105 for intermediate/high-risk myelofibrosis
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
Hefei, AnhuiAges 18 years+ - NCT07649525RecruitingPhase 3
Personalized myeloma treatment based on response and fitness
This trial tests whether tailoring myeloma treatment based on how well you respond to initial therapy and your overall health status can improve outcomes. You'll receive standard first-line treatment (three drugs: daratumumab, lenalidomide, and dexamethasone) and then be assigned to a personalized pathway based on your response and fitness level.
BristolAges 18 years+ - NCT05189925RecruitingPhase 1
Correcting a missing immune enzyme using an mRNA cell therapy
This early-phase trial tests whether an mRNA-based treatment can correct a key immune problem in people with chronic granulomatous disease (CGD). It may help your immune cells work better against infections, but this is mainly to check safety and early signs of benefit.
Bethesda, MarylandAges 18–75 - NCT07372131Recruiting
Shorter antibiotics for high-risk fever with low white blood cells
This study looks at how long antibiotics should be given to cancer patients with fever and very low white blood cell counts after finding a certain type of bacteria (Gram-negative) in their blood. The goal is to find the best treatment duration to help patients recover without complications.
Rozzano, MilanAges 18 years+ - NCT02958462Recruiting
Clinic study for early blood or bone marrow warning signs
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
Scottsdale, ArizonaAges 18 years+ - NCT02964858Recruiting
Testing the best radiation dose after R-CHOP for lymphoma
This trial studies how to choose the safest and most effective radiation dose for diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma) after standard chemotherapy. It may help improve disease control while aiming to limit side effects from radiation.
Mumbai, MaharashtraAges 18–65 - NCT02967068Recruiting
Share your study tissue for future research
This study is a “tissue repository” that collects and stores leftover tissue from other approved VCRC studies. If you already took part in one of those studies, you may be able to let researchers use your tissue to help answer future questions.
Boston, MassachusettsAges Any age - NCT02979119Recruiting
Haemophilia patient registry for children across Europe
This trial is a patient registry that collects medical information from children with hemophilia A or B. It may help care teams better understand bleeding patterns and treatments over time across participating hospitals.
GrazAges Any age - NCT02982902RecruitingEarly Phase 1
T cell treatment for stubborn CMV after stem cell transplant
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
Cleveland, OhioAges 3 months+ - NCT02990572Recruiting
Join an Amish and Mennonite research participant registry
This study builds a contact registry of Amish and Mennonite people so researchers can reach you about future studies. It may help you get notified about research opportunities that fit your community.
Pittsburgh, PennsylvaniaAges Any age - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT03049254Recruiting
Registry and blood/tissue study for certain sudden heart death causes
This study builds a registry and collection of samples to better understand families affected by sudden heart death and related heart rhythm problems that are not clearly caused by a heart attack. It may help researchers identify patterns and improve future care, and it offers a way for patients and families to contribute to research.
Rochester, MinnesotaAges Any age - NCT03055247RecruitingPhase 2
Try ibuprofen plus growth factor and stem-cell mobilizer for X-CGD
This trial tests a combination of medicines to help your body release (“mobilize”) stem cells for future treatment in people with X-linked chronic granulomatous disease (X-CGD). If it works well and is safe for you, it may make stem-cell collection easier and more successful.
Rome, LazioAges 18–45 - NCT03058588Recruiting
Genetic testing study for inherited AML or MDS risk
This study uses advanced DNA testing to look for inherited gene changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It may help explain whether your illness could be part of a family-linked risk syndrome, which can guide treatment and family planning.
BresciaAges Any age - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT03094026Recruiting
Practice cognitive training after a transplant
This study tests whether a structured cognitive training program can help people think and remember better after an allogeneic stem cell transplant. It may also explore how people feel about genetics and genetic testing.
Birmingham, AlabamaAges 21 years+ - NCT03104491RecruitingPhase 1/Phase 2
Inotuzumab after transplant for CD22-positive leukemia
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Westwood, KansasAges 16–75 - NCT03110822RecruitingPhase 1
Ruxolitinib, steroids, and lenalidomide for hard-to-treat myeloma
This Phase 1 trial tests a combination of ruxolitinib plus steroids and lenalidomide in people with relapsed or refractory multiple myeloma. It’s designed for patients who have had at least two prior treatment options and whose myeloma is getting worse or not responding.
Alhambra, CaliforniaAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03117010Recruiting
Study of adults with suspected or confirmed HLH
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
SeoulAges 18–80 - NCT03117036Recruiting
Study follows people with Hodgkin or non-Hodgkin lymphoma
This study enrolls adults with Hodgkin or non-Hodgkin lymphoma who plan to receive chemotherapy aimed at cure. It may help doctors better understand outcomes and how lymphoma care is managed over time.
SeoulAges 20–90
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.